Journal
CANCERS
Volume 11, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/cancers11050616
Keywords
head and neck squamous cell carcinoma; HNSCC; cancer stem cells; therapy resistance; biomarkers
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG) [273676790, 401326337, 416001651]
- Wilhelm Sander-Stiftung [2017.106.1]
- BMBF [03Z1NN11]
- DLR Project Management Agency [01DK17047]
Ask authors/readers for more resources
Head and neck squamous cell carcinoma (HNSCC) is the sixth most commonly diagnosed cancer worldwide. Despite advances in the treatment management, locally advanced disease has a poor prognosis, with a 5-year survival rate of approximately 50%. The growth of HNSCC is maintained by a population of cancer stem cells (CSCs) which possess unlimited self-renewal potential and induce tumor regrowth if not completely eliminated by therapy. The population of CSCs is not only a promising target for tumor treatment, but also an important biomarker to identify the patients at risk for therapeutic failure and disease progression. This review aims to provide an overview of the recent pre-clinical and clinical studies on the biology and potential therapeutic implications of HNSCC stem cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available